近年来转移性结直肠癌靶向治疗研究进展
Recent Research Progress in Targeted Ther-apy of Metastatic Colorectal Cancer
摘要: 结直肠癌(colorectal cancer, CRC)是常见消化系统肿瘤，发病具有隐匿性，转移是导致结直肠癌患者死亡的一个主要原因，在整个疾病进程中几乎一半的患者会发生转移，约25%患者确诊时已处于晚期阶段，出现病灶转移。转移性结直肠癌(mCRC)通常无手术机会且传统化疗效果欠佳，病死率高。目前临床治疗mCRC主要依靠放疗、化疗及分子靶向治疗综合治疗，近年来分子靶向治疗成为mCRC治疗新方向，尤其是近年来分子靶向药物贝伐珠单抗及西妥昔单抗问世并广泛应用于临床，mCRC预后显著改善。本文就目前mCRC靶向治疗的研究进展进行综述，以期为临床诊疗提供依据。
Abstract: Colorectal cancer (CRC) is a common digestive system tumor with occult onset, and metastasis is a major cause of death in colorectal cancer patients. In the entire course of the disease, almost half of patients have metastases, and about 25% of patients are diagnosed with colorectal cancer in the advanced stage, focus metastasis. Metastatic colorectal cancer (mCRC) usually has no surgical op-portunity and is less effective with conventional chemotherapy, with high mortality. Currently, the clinical treatment of mCRC mainly relies on the combination of radiotherapy, chemotherapy and molecular targeted therapy. In recent years, molecular targeted therapy has become a new direc-tion of mCRC treatment, especially in recent years, molecular targeted drugs bevacizumab and ce-tuximab have been developed and widely used in clinic, and the prognosis of mCRC has been signif-icantly improved. This article reviews the current research progress of mCRC targeted therapy, in order to provide evidence for clinical diagnosis and treatment.
文章引用：张婷婷, 郭建强. 近年来转移性结直肠癌靶向治疗研究进展[J]. 临床医学进展, 2023, 13(6): 10321-10328. https://doi.org/10.12677/ACM.2023.1361445

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Arnold, M., Sierra, M.S., Laversanne, M., et al. (2017) Global Patterns and Trends in Colorectal Cancer Incidence and Mortality. Gut, 66, 683-691. [Google Scholar] [CrossRef] [PubMed]
[3] Garcia, J., Hurwitz, H.I., Sandler, A.B., et al. (2020) Bevaci-zumab (Avastin®) in Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook. Cancer Treatment Reviews, 86, Article ID: 102017. [Google Scholar] [CrossRef] [PubMed]
[4] Alfonso, P.G. (2018) Chemotherapy plus Bevacizumab as Neoad-juvant or Conversion Treatment in Patients with Colorectal Liver Metastases. Anticancer Research, 38, 3069-3077. [Google Scholar] [CrossRef] [PubMed]
[5] 钱健, 秦超, 殷长军. 肿瘤靶向药物疗效及毒性与基因多态性间相关性的研究进展[J]. 中国肿瘤外科杂志, 2012, 4(3): 161-163.
[6] Simanshu, D.K., Nissley, D.V. and McCor-mick, F. (2017) RAS Proteins and Their Regulators in Human Disease. Cell, 170, 17-33. [Google Scholar] [CrossRef] [PubMed]
[7] Salomon, D.S., Brandt, R., Ciardiello, F., et al. (1995) Epidermal Growth Factor-Related Peptides and Their Receptors in Human Malignancies. Critical Reviews in Oncology/Hematology, 19, 183-232. [Google Scholar] [CrossRef] 
[8] Parseghian, C.M., Napolitano, S., Loree, J.M., et al. (2019) Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clinical Cancer Research, 25, 6899-6908. [Google Scholar] [CrossRef] 
[9] Parseghian, C.M., Loree, J.M., Morris, V.K., et al. (2019) Anti-EGFR-Resistant Clones Decay Exponentially after Progression: Implications for Anti-EGFR Re-Challenge. Annals of Oncology, 30, 243-249. [Google Scholar] [CrossRef] [PubMed]
[10] Rowland, A., Dias, M.M., Wiese, M.D., et al. (2015) Meta-Analysis of BRAF Mutation as a Predictive Biomarker of Benefit from Anti-EGFR Monoclonal Antibody Therapy for RAS Wild-Type Metastatic Colorectal Cancer. British Journal of Cancer, 112, 1888-1894. [Google Scholar] [CrossRef] [PubMed]
[11] De Roock, W., Claes, B., Bernasconi, D., et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA Mutations on the Efficacy of Cetuximab plus Chemotherapy in Chemotherapy-Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis. The Lancet Oncology, 11, 753-762. [Google Scholar] [CrossRef] 
[12] Sakata, S. and Larson, D.W. (2022) Targeted Therapy for Colorectal Cancer. Surgical Oncology Clinics of North America, 31, 255-264. [Google Scholar] [CrossRef] [PubMed]
[13] Bhattacharya, S. (2023) An Empirical Review on the Resistance Mechanisms of Epidermal Growth Factor Receptor Inhibitors and Predictive Molecular Biomarkers in Colorectal Cancer. Critical Reviews in Oncology/Hematology, 183, Article ID: 103916. [Google Scholar] [CrossRef] [PubMed]
[14] Kawai, S., Takeshima, N., Hayasaka, Y., et al. (2021) Com-parison of Irinotecan and Oxaliplatin as the First-Line Therapies for Metastatic Colorectal Cancer: A Meta-Analysis. BMC Cancer, 21, Article No. 116. [Google Scholar] [CrossRef] [PubMed]
[15] Cremolini, C., Antoniotti, C., Lonardi, S., et al. (2018) Activity and Safety of Cetuximab plus Modified FOLFOXIRI Followed by Maintenance with Cetuximab or Bevacizumab for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. JAMA Oncology, 4, 529-536. [Google Scholar] [CrossRef] [PubMed]
[16] Modest, D.P., Martens, U.M., Riera-Knorrenschild, J., et al. (2019) FOLFOXIRI plus Panitumumab as First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). Journal of Clinical Oncology, 37, 3401-3411. [Google Scholar] [CrossRef] 
[17] Amodio, V., Yaeger, R., Arcella, P., et al. (2020) EGFR Blockade Re-verts Resistance to KRAS(G12C) Inhibition in Colorectal Cancer. Cancer Discovery, 10, 1129-1139. [Google Scholar] [CrossRef] 
[18] Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., et al. (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. The New England Journal of Medicine, 359, 1757-1765. [Google Scholar] [CrossRef] 
[19] Shin, A.E., Giancotti, F.G. and Rustgi, A.K. (2023) Metastatic Col-orectal Cancer: Mechanisms and Emerging Therapeutics. Trends in Pharmacological Sciences, 44, 222-236. [Google Scholar] [CrossRef] [PubMed]
[20] Tan, L., Tran, B., Tie, J., et al. (2023) A Phase Ib/II Trial of Com-bined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib in Combination Trial) Study. Clinical Cancer Research, 29, 1017-1030. [Google Scholar] [CrossRef] 
[21] Dinu, I.M., Mihăilă, M., Diculescu, M.M., et al. (2023) Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice. Medicina (Kaunas), 59, Article No. 350. [Google Scholar] [CrossRef] [PubMed]
[22] Rosen, L.S., Jacobs, I.A. and Burkes, R.L. (2017) Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology, 12, 599-610. [Google Scholar] [CrossRef] [PubMed]
[23] Carmeliet, P. and Jain, R.K. (2011) Principles and Mechanisms of Vessel Normalization for Cancer and Other Angiogenic Diseases. Nature Reviews Drug Discovery, 10, 417-427. [Google Scholar] [CrossRef] [PubMed]
[24] Mariotti, V., Fiorotto, R., Cadamuro, M., et al. (2021) New Insights on the Role of Vascular Endothelial Growth Factor in Biliary Pathophysiology. JHEP Reports, 3, Article ID: 100251. [Google Scholar] [CrossRef] [PubMed]
[25] Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004) Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. The New England Journal of Medicine, 350, 2335-2342. [Google Scholar] [CrossRef] 
[26] Cremolini, C., Antoniotti, C., Rossini, D., et al. (2020) Upfront FOLFOXIRI plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 plus Bevacizumab Followed by FOLFIRI plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial. The Lancet Oncology, 21, 497-507. [Google Scholar] [CrossRef] 
[27] Grothey, A., Van Cutsem, E., Sobrero, A., et al. (2013) Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicen-tre, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 381, 303-312. [Google Scholar] [CrossRef] 
[28] Creasy, J.M., Sadot, E., Koerkamp, B.G., et al. (2018) The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Co-lon Cancer. Annals of Surgical Oncology, 25, 431-438. [Google Scholar] [CrossRef] [PubMed]
[29] Tabernero, J., Yoshino, T., Cohn, A.L., et al. (2015) Ramu-cirumab versus Placebo in Combination with Second-Line FOLFIRI in Patients with Metastatic Colorectal Carcinoma That Progressed during or after First-Line Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE): A Randomised, Double-Blind, Multicentre, Phase 3 Study. The Lancet Oncology, 16, 499-508. [Google Scholar] [CrossRef] 
[30] Valverde, A., Peñarando, J., Cañas, A., et al. (2015) Simul-taneous Inhibition of EGFR/VEGFR and Cyclooxygenase-2 Targets Stemness-Related Pathways in Colorectal Cancer Cells. PLOS ONE, 10, e131363. [Google Scholar] [CrossRef] [PubMed]
[31] Ahcene, D.S., Daniel, F., Milani, A., et al. (2022) HER2 in Colorectal Cancer: The Long and Winding Road from Negative Predictive Factor to Positive Actionable Target. American Society of Clinical Oncology Educational Book, 42, 1-14.
[32] Yonesaka, K., Zejnullahu, K., Okamoto, I., et al. (2011) Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. Science Translational Medicine, 3, 86r-99r. [Google Scholar] [CrossRef] [PubMed]
[33] Bertotti, A., Migliardi, G., Galimi, F., et al. (2011) A Molecu-larly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 1, 508-523. [Google Scholar] [CrossRef] 
[34] Matallanas, D., Birtwistle, M., Romano, D., et al. (2011) Raf Family Kinases: Old Dogs Have Learned New Tricks. Genes Cancer, 2, 232-260. [Google Scholar] [CrossRef] [PubMed]
[35] Davies, H., Bignell, G.R., Cox, C., et al. (2002) Mutations of the BRAF Gene in Human Cancer. Nature, 417, 949-954. [Google Scholar] [CrossRef] [PubMed]
[36] Kopetz, S., Desai, J., Chan, E., et al. (2015) Phase II Pilot Study of Vemurafenib in Patients with Metastatic BRAF-Mutated Colorectal Cancer. Journal of Clinical Oncology, 33, 4032-4038. [Google Scholar] [CrossRef] 
[37] Kopetz, S., Guthrie, K.A., Morris, V.K., et al. (2021) Randomized Trial of Irinotecan and Cetuximab with or without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of Clinical Oncology, 39, 285-294. [Google Scholar] [CrossRef] 
[38] Wang, Z., Qin, B.D., Ye, C.Y., et al. (2022) Cetuximab and Vemurafenib plus FOLFIRI (5-Fluorouracil/Leucovorin/ Irinotecan) for BRAF V600E-Mutated Advanced Colorectal Cancer (Improvement): An Open-Label, Single-Arm, Phase II Trial. Euro-pean Journal of Cancer, 163, 152-162. [Google Scholar] [CrossRef] [PubMed]
[39] Corcoran, R.B., Atreya, C.E., Falchook, G.S., et al. (2015) Combined BRAF and MEK Inhibition with Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. Journal of Clinical Oncology, 33, 4023-4031. [Google Scholar] [CrossRef] 
[40] Chen, L. (2004) Co-Inhibitory Molecules of the B7-CD28 Family in the Control of T-Cell Immunity. Nature Reviews Immunology, 4, 336-347. [Google Scholar] [CrossRef] [PubMed]
[41] Le, D.T., Uram, J.N., Wang, H., et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine, 372, 2509-2520. [Google Scholar] [CrossRef] 
[42] Sherman, E., Lee, J.L., Debruyne, P.R., et al. (2023) Safety and Ef-ficacy of Cobimetinib plus Atezolizumab in Patients with Solid Tumors: A Phase II, Open-Label, Multicenter, Multico-hort Study. ESMO Open, 8, Article ID: 100877. [Google Scholar] [CrossRef] [PubMed]
[43] Overman, M.J., Lonardi, S., Wong, K., et al. (2018) Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. Journal of Clinical Oncology, 36, 773-779. [Google Scholar] [CrossRef] 
[44] Sawayama, H., Miyamoto, Y., Ogawa, K., et al. (2020) Investiga-tion of Colorectal Cancer in Accordance with Consensus Molecular Subtype Classification. Annals of Gastroenterologi-cal Surgery, 4, 528-539. [Google Scholar] [CrossRef] [PubMed]
[45] Motta, R., Cabezas-Camarero, S., Torres-Mattos, C., et al. (2021) Immu-notherapy in Microsatellite Instability Metastatic Colorectal Cancer: Current Status and Future Perspectives. Journal of Clinical and Translational Research, 7, 511-522.
[46] Weng, J., Li, S., Zhu, Z., et al. (2022) Exploring Immunotherapy in Colorectal Cancer. Journal of Hematology & Oncology, 15, Article No. 95. [Google Scholar] [CrossRef] [PubMed]

为你推荐